ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 637

Anti-Mullerian Hormone and Ovarian Reserve in Systemic Lupus Erythematosus

Chi Chiu Mok1, Pak To Chan2 and Chi Hung To2, 1Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, 2Medicine, Hong Kong, Hong Kong

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: hormones

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus: Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose: To study the level of anti-mullerian hormone (AMH) and its relationship with age and previous cyclophosphamide (CYC) exposure in patients with systemic lupus erythematosus (SLE).

Methods: Consecutive female patients aged 18-52 years who had menstruation in the preceding 12 months and fulfilled ³4 ACR criteria for SLE were recruited.  AMH was assayed by an ELISA kit (Beckman Coulter, Inc., USA).  Serum AMH level was compared between patients with and without previous use of immunosuppressive agents. The relationship of AMH level to age and CYC exposure was studied by linear regression.

Results: 216 female SLE patients were studied. The mean age of patients at the time of venepuncture was 35.1±10.1 years and the mean SLE duration was 7.6±5.9 years.  Immunosuppressive drugs ever received by these patients were: prednisolone (90%), AZA (69%), MMF (30%), tacrolimus (21%), cyclosporin A (17%), CYC (22%) and HCQ (67%).  Prednisolone was exclusively used in combination with one or more of the other immunosuppressive drugs.  Of the 48 CYC users, 29 (40%) received daily oral treatment and 19 (40%) received monthly intravenous pulse therapy.  The median total duration of CYC exposure was 20 weeks (inter-quartile range [IQR] 12.3-32.8).  Fifty-four (25%) patients had undetectable AMH level (78% aged >40 years).  These patients were significantly older than those with measurable AMH level (median age 47 [IQR 42-51] vs 31 [IQR 25-38.3] years; p<0.001).  Significantly lower levels of AMH were observed for past users of CYC than non-users, after adjustment for age (1.58±2.92 vs 1.73±2.11 ng/mL; p=0.04 by ANCOVA).  The mean time interval between AMH assay and last dose of CYC administered was 6.28±3.8 years.  AMH levels were not statistically different between users and non-users of other immunosuppressive agents that included prednisolone, mycophenolate mofetil, azathioprine and the calcineurin inhibitors.  Linear regression revealed age (Beta -0.32; p=0.02) and each 5g of CYC exposure (Beta -0.28; p=0.047) were independently associated with lower AMH level.  The route of CYC administration, duration of CYC treatment, disease activity score and duration of SLE was not significantly associated with AMH level on univariate regression analyses.

Conclusion: AMH is a sensitive marker for ovarian damage due to previous CYC treatment in SLE patients.


Disclosure:

C. C. Mok,
None;

P. T. Chan,
None;

C. H. To,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-mullerian-hormone-and-ovarian-reserve-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology